Key Points
- Major shareholder Timothy Lynch purchased 1.15 million AEON Biopharma shares at $0.21 each, investing $241,500 and increasing his ownership by 21.5% to 6.5 million shares.
- AEON shares opened at $0.19, near their 52-week low of $0.18, with a market capitalization of approximately $4.86 million. Institutional investors own 22.78% of the company, while XTX Topco increased its stake by 251.8% during the fourth quarter.
- Analyst sentiment remains a “Moderate Buy”, with three Buy ratings and one Hold rating and an average price target of $1.10, though HC Wainwright recently lowered its target to $1.20 from $5.00.
AEON Biopharma, Inc. (NASDAQ:AEON - Get Free Report) major shareholder Timothy Lynch purchased 1,150,000 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was purchased at an average price of $0.21 per share, with a total value of $241,500.00. Following the completion of the transaction, the insider owned 6,500,000 shares of the company's stock, valued at approximately $1,365,000. This trade represents a 21.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
AEON Biopharma Stock Performance
AEON opened at $0.19 on Friday. AEON Biopharma, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $1.45. The firm's fifty day moving average is $0.44 and its 200 day moving average is $0.78. The stock has a market cap of $4.86 million, a price-to-earnings ratio of 1.07 and a beta of 0.65.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in AEON Biopharma stock. XTX Topco Ltd lifted its holdings in AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) by 251.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,852 shares of the company's stock after buying an additional 40,690 shares during the quarter. XTX Topco Ltd owned approximately 0.48% of AEON Biopharma worth $63,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.78% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on AEON. Zacks Research raised AEON Biopharma to a "hold" rating in a research note on Wednesday, May 27th. HC Wainwright reaffirmed a "buy" rating and set a $1.20 target price (down from $5.00) on shares of AEON Biopharma in a research note on Friday, August 14th. Finally, Lake Street Capital initiated coverage on AEON Biopharma in a research report on Thursday, July 30th. They issued a "buy" rating and a $1.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, AEON Biopharma has an average rating of "Moderate Buy" and an average price target of $1.10.
Read Our Latest Stock Report on AEON Biopharma
AEON Biopharma Company Profile
(
Get Free Report)
AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.
Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
